Kure Advisory’s AbbVie ABBV Stock Holding History

Kure Advisory’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,884	Closed	-$292K	–	38
2023 Q4	$292K	Buy	1,884 +21	+1%	+$3.06K	0.15%	79
2023 Q3	$278K	Buy	+1,863	New	+$273K	0.16%	76

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Kure Advisory's ABBV Position: Q1 2024 in Review

Kure Advisory sold out of AbbVie (ABBV) in Q1 2024, closing a stake of 1,884 shares — an estimated $292K sold.

Kure Advisory first reported a position in ABBV in Q3 2023 and held it in 2 quarters. The position peaked at $292K in Q4 2023. 3,379 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.

Kure Advisory reported no remaining AbbVie position as of Q1 2024 after selling out during the quarter.
Kure Advisory sold 1,884 AbbVie shares in Q1 2024, an estimated $292K.
Kure Advisory first reported a position in AbbVie in Q3 2023 and held it in 2 quarters.
Kure Advisory's AbbVie position peaked at $292K in Q4 2023.
3,379 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.

Based on Kure Advisory's 13F filing for Q1 2024, filed 9 May 2024.